Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy.

NCT05832593 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2023-04-27

No results posted yet for this study

Summary

1. Determine the correlation between immunohistochemical expression of ERCC1 in laryngeal cancer cells with clinico-pathological variables.
2. Assess the correlation between ERCC1 expression and response to radiotherapy.

Conditions

  • Laryngeal Squamous Cell Carcinoma

Interventions

OTHER

Immunohistochemistry

Immunohistochemical expression of ERCC1

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2024-10-31
Completion
2025-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05832593 on ClinicalTrials.gov